INNOVENT BIO (01801) surged more than 4%, reaching HK$98 by the time of writing, with a trading volume of HK$405 million. On November 25, the company announced that the marketing application for Xermelo® (Mazdutide Injection, a glucagon "GCG"/glucagon-like peptide-1 "GLP-1" dual receptor agonist) in a high-dose 9mg formulation for long-term weight control in adults with moderate-to-severe obesity has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). Mazdutide is expected to provide a potent and safe new treatment option for Chinese patients with moderate-to-severe obesity, beyond weight-loss surgery.
The application is based on the outstanding results from the Phase III registration clinical trial GLORY-2 (NCT06164873) for Mazdutide 9mg in Chinese patients with moderate-to-severe obesity. The study recently met its primary endpoint and all key secondary endpoints. Xermelo® (Mazdutide Injection) 9mg is currently the only GLP-1-based therapy that achieves over 20% weight loss after one year of treatment with just a two-step dose titration. Its development provides evidence-based medical support for effective weight management in Chinese patients with moderate-to-severe obesity, offering an alternative to surgical interventions.
Comments